18F-FDG PET-CT in the clinical management of cardiac sarcoidosis: A regional academic referral center experience.

Conclusion 18F-FDG PET-CT is an effective tool in the clinical management of CS, including its initial diagnosis and assessment following therapy. Although not statistically significant, patients treated for a longer duration were more likely to respond to the therapy. Additionally, dual immunomodulator therapy with prednisone and methotrexate may improve therapeutic response in CS. Figure 1. F-18 FDG PET-CT MIP and axial fused PET-CT images showing (A) focal on diffuse hypermetabolic activity in the left ventricular myocardium consistent with cardiac sarcoidosis, and (B) resolution of the myocardial activity following immunomodulator therapy. It is important to note the scans also revealed persistent pulmonary, as well as mediastinal and hilar nodal involvement.

Source: Journal of Nuclear Medicine - May 23, 2018 Category: Nuclear Medicine Authors: Rieter, W., Burchett, P., De Cecco, C., James, W., Hargrave, P., Nance, J., Gordon, L. Tags: Cardiovascular Clinical Science Poster Session Source Type: research